Royalty Pharma Acquires Memorial Sloan-Kettering Cancer Center’s International Royalty Interest in Neupogen® and Neulasta® for $142 Million

New York, NY, August 22, 2005 – Royalty Pharma and Memorial Sloan-Kettering Cancer Center (“MSKCC”) announced today that they have completed the sale of a portion of MSKCC’s royalty interest in Neupogen® and Neulasta® worldwide for all countries except the United States, China, Japan, South Korea, North Korea and Taiwan.

Source: Original Article